[go: up one dir, main page]

EE04120B1 - Viirusevastase bensimidasoolühendi kristallilisedvormid - Google Patents

Viirusevastase bensimidasoolühendi kristallilisedvormid

Info

Publication number
EE04120B1
EE04120B1 EEP200000584A EEP200000584A EE04120B1 EE 04120 B1 EE04120 B1 EE 04120B1 EE P200000584 A EEP200000584 A EE P200000584A EE P200000584 A EEP200000584 A EE P200000584A EE 04120 B1 EE04120 B1 EE 04120B1
Authority
EE
Estonia
Prior art keywords
crystalline forms
benzimidazole compound
antiviral
antiviral benzimidazole
compound
Prior art date
Application number
EEP200000584A
Other languages
English (en)
Estonian (et)
Inventor
Howard Carter Barry
Neal Glover Bobby
Huang Lian-Feng
William Lancaster Robert
Todd Long Stacey
Catherine Rizzolio Michele
Allen Schmitt Eric
Riddle Sickles Barry
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000584A publication Critical patent/EE200000584A/xx
Publication of EE04120B1 publication Critical patent/EE04120B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200000584A 1998-04-07 1999-04-01 Viirusevastase bensimidasoolühendi kristallilisedvormid EE04120B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807354.7A GB9807354D0 (en) 1998-04-07 1998-04-07 Antiviral compound
PCT/EP1999/002214 WO1999051618A1 (en) 1998-04-07 1999-04-01 Novel crystalline forms of an antiviral benzimidazole compound

Publications (2)

Publication Number Publication Date
EE200000584A EE200000584A (et) 2002-04-15
EE04120B1 true EE04120B1 (et) 2003-08-15

Family

ID=10829932

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000584A EE04120B1 (et) 1998-04-07 1999-04-01 Viirusevastase bensimidasoolühendi kristallilisedvormid

Country Status (28)

Country Link
US (9) US6469160B1 (no)
EP (1) EP1071693B1 (no)
JP (1) JP2002510703A (no)
KR (1) KR20010074472A (no)
CN (1) CN1303390A (no)
AP (1) AP2000001947A0 (no)
AT (1) ATE261452T1 (no)
AU (1) AU752877B2 (no)
BR (1) BR9909474A (no)
CA (1) CA2327494C (no)
DE (1) DE69915461T2 (no)
EA (1) EA002970B1 (no)
EE (1) EE04120B1 (no)
ES (1) ES2216503T3 (no)
GB (1) GB9807354D0 (no)
HR (1) HRP20000669A2 (no)
HU (1) HUP0101669A3 (no)
ID (1) ID27109A (no)
IL (1) IL138697A0 (no)
IS (1) IS5640A (no)
NO (1) NO20005005L (no)
NZ (1) NZ507173A (no)
PL (1) PL343397A1 (no)
SK (1) SK14832000A3 (no)
TR (1) TR200002860T2 (no)
WO (1) WO1999051618A1 (no)
YU (1) YU60900A (no)
ZA (1) ZA200005153B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
SI1567529T2 (sl) 2002-05-16 2021-08-31 Janssen Sciences Ireland Unlimited Company Psevdopolimorfne oblike zaviralca HIV proteaze
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
US9198862B2 (en) * 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
EP1928826B1 (en) * 2005-09-21 2013-04-24 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007053427A2 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
RU2496780C2 (ru) * 2006-10-27 2013-10-27 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Твердые формы
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR101043794B1 (ko) * 2009-04-13 2011-06-27 청우산업 주식회사 황토판재로 제공되는 기능성 황토방
BR112012022910B1 (pt) 2010-03-12 2021-08-10 Omeros Corporation Compostos inibidores de pde10, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos para tratar distúrbios neurológicos em um animal de sangue quente
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
US8940707B2 (en) 2010-10-28 2015-01-27 Viropharma Incorporated Maribavir isomers, compositions, methods of making and methods of using
US8546344B2 (en) * 2010-10-28 2013-10-01 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
EP4480956A3 (en) 2022-10-12 2025-02-19 Takeda Pharmaceutical Company Limited Viral inhibitors, the synthesis thereof, and intermediates thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399987A (en) * 1965-08-02 1968-09-03 United States Borax Chem 2-alkylaminobenzimidazoles as herbicides
CH443777A (de) * 1965-08-06 1968-02-15 Agripat Sa Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens
US3655901A (en) * 1970-07-30 1972-04-11 Merck & Co Inc Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
WO1994008456A1 (en) * 1992-10-21 1994-04-28 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound

Also Published As

Publication number Publication date
HUP0101669A3 (en) 2003-07-28
HRP20000669A2 (en) 2001-08-31
PL343397A1 (en) 2001-08-13
BR9909474A (pt) 2000-12-19
ES2216503T3 (es) 2004-10-16
DE69915461T2 (de) 2005-03-03
ATE261452T1 (de) 2004-03-15
EA200000911A1 (ru) 2001-04-23
SK14832000A3 (sk) 2001-07-10
US20110118203A1 (en) 2011-05-19
JP2002510703A (ja) 2002-04-09
AU3603499A (en) 1999-10-25
KR20010074472A (ko) 2001-08-04
CA2327494C (en) 2010-10-26
US20170002035A1 (en) 2017-01-05
NO20005005L (no) 2000-12-06
US9163052B2 (en) 2015-10-20
US20180044366A1 (en) 2018-02-15
AU752877B2 (en) 2002-10-03
WO1999051618A1 (en) 1999-10-14
EP1071693A1 (en) 2001-01-31
US7714123B2 (en) 2010-05-11
NZ507173A (en) 2003-07-25
TR200002860T2 (tr) 2000-12-21
HUP0101669A2 (hu) 2001-10-28
IS5640A (is) 2000-09-26
CN1303390A (zh) 2001-07-11
GB9807354D0 (en) 1998-06-03
ZA200005153B (en) 2001-09-26
DE69915461D1 (de) 2004-04-15
US20080103186A1 (en) 2008-05-01
CA2327494A1 (en) 1999-10-14
AP2000001947A0 (en) 2000-12-31
YU60900A (sh) 2003-07-07
IL138697A0 (en) 2001-10-31
US20100179101A1 (en) 2010-07-15
US20130261294A1 (en) 2013-10-03
ID27109A (id) 2001-03-01
US7297683B2 (en) 2007-11-20
US6469160B1 (en) 2002-10-22
US20160030460A1 (en) 2016-02-04
EP1071693B1 (en) 2004-03-10
US20020177703A1 (en) 2002-11-28
EA002970B1 (ru) 2002-12-26
NO20005005D0 (no) 2000-10-04
EE200000584A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
EE200000584A (et) Viirusevastase bensimidasoolühendi kristallilisedvormid
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
NO20015536D0 (no) FAP-aktiverte anti-tumor-forbindelser
NO20011745L (no) Forbindelser
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
NO20005795D0 (no) Antivirale forbindelser
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
DE50009640D1 (de) Drehmaschine
ID27004A (id) Senyawa-senyawa kalsilitik
NO20013684D0 (no) Substituerte fenetylaminderivater
ID30516A (id) Senyawa-senyawa (aminoiminometil atau aminometil) benzoheteroaril tersubstitusi
NO20006662D0 (no) Fluorfenylresin-forbindelser
DK1054867T3 (da) Antivirale midler
IS5821A (is) Kristalluð form af ósanetant
FI982378A0 (fi) Järjestely kohteen tutkimiseen
PT1175417E (pt) Compostos substituidos de benzolactamas
DE60024760D1 (de) Einlagerungsverbindung
DE59910977D1 (de) Motorradverkleidung
IT250476Y1 (it) Struttura di elemento di aggancio particolarmente per la connessionereciproca di due parti
ITMI982758A1 (it) Procedimento per la purificazione di 7-glutaril aca
HK1032973A (en) Novel crystalline forms of an antiviral benzimidazole compound
IT1302547B1 (it) Struttura multistrato per la realizzazione di elementi diprotezione
SE9904417D0 (sv) Crystalline form
FI980433A0 (fi) Foerfarande foer utnyttjande i samband med tillslutandet av en vaetskefoerpackning

Legal Events

Date Code Title Description
HD1A Correction of address
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20050401